Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPersimmon Regulatory News (PSN)

Share Price Information for Persimmon (PSN)

Share Price is delayed by 15 minutes
Get Live Data
1,074.00    37.00 (3.57%)
Bid:
1,073.50
Ask:
1,074.50
Spread: 1.00 (0.093%)
Market Cap: £3.45b
PSN Live PriceLast checked at - London Stock Exchange

Intraday Persimmon Share Chart

Directorate Change

9 Jan 2012 07:00

RNS Number : 1766V
Persimmon PLC
09 January 2012
 

 

Persimmon Plc

 

Appointment of Mark Preston as non-executive Director

Director: Change of responsibilities

 

 

1. Appointment of Mark Preston as a non-executive director

 

Persimmon Plc is pleased to announce the appointment of Mark Preston as non-executive Director with effect from 9 January 2012.

 

Mark Preston (43), a chartered surveyor, is the Group Chief Executive of Grosvenor Group Limited, an appointment he took up in 2008. He is also a non-executive Director of Sonae Sierra SGPS.

 

Nicholas Wrigley, Chairman of Persimmon, said: "We are delighted to welcome Mark to the Board. He has a wealth of experience and expertise which will be of great benefit to Persimmon as we continue to develop our business."

 

No further information is required to be disclosed pursuant to Listing Rule 9.6.13.

 

 

2. Director - change of responsibilities

 

With effect from 9 January 2012 Jeff Fairburn (45), will be promoted to Group Managing Director with responsibility for Group operational functions and management of the Group's strategic land portfolio.

 

Jeff joined Persimmon in 1989 and was appointed to the Board on 1 June 2009. He will continue as North Division Chief Executive.

 

Mike Farley, Group Chief Executive of Persimmon said: "Jeff has been with Persimmon for over 20 years and brings a wealth of knowledge and experience to this important newly created role. I'm confident that he will bring even greater focus to the key areas of strategic land and operational efficiency that are vital to the Group's continued success."

 

 

Notes to Editors:

 

About Mark Preston

 

Mark Preston (43), a chartered surveyor, is the Group Chief Executive of Grosvenor Group Limited. Mark joined Grosvenor in the UK in 1989 and became Chief Executive of Grosvenor Britain & Ireland in 2006 and Group Chief Executive in 2008.

 

He is a non-executive Director of Sonae Sierra SGPS. He is also a Director of The Association of Foreign Investors in Real Estate, a Member of the (University of) Cambridge Land Economy Advisory Board and a Member of the Eurohypo International Advisory Board.

 

 

 

About Persimmon

Persimmon plc was established in 1972 and has become one of Britain's leading housebuilders. The Group's Head Office is in York and Persimmon has 25 offices nationwide. The Group operates under three main brands; Persimmon Homes, Charles Church and Westbury Partnerships.

 

The Persimmon Homes business builds quality houses which provide the very best in design, construction and service. Charles Church provides a range of premium houses, in both modern and traditional styles. Westbury Partnerships focuses on social housing using modern methods of construction supplied by Space4, our timber frame manufacturing business.

 

For more information about Persimmon please go to www.corporate.persimmonhomes.com

 

 

 

 

For further information, please contact:

Simon Rigby

Kevin Smith

Lindsay Noton

Mike Farley, Group Chief Executive

Mike Killoran, Group Finance Director

Persimmon plc

Tel: +44 (0) 1904 642199

Citigate Dewe Rogerson

Tel: +44 (0) 20 7638 9571

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BOAUNABRUWAARAR
Date   Source Headline
1st May 20252:20 pmRNSResult of AGM
1st May 20252:02 pmRNSTotal Voting Rights
1st May 20257:00 amRNSAGM Trading Statement
25th Apr 202510:54 amRNSHolding(s) in Company
25th Apr 20259:24 amRNSHolding(s) in Company
11th Apr 20254:22 pmRNSHolding(s) in Company
3rd Apr 202510:15 amRNSHolding(s) in Company
2nd Apr 202512:22 pmRNSHolding(s) in Company
1st Apr 202512:03 pmRNSTotal Voting Rights
31st Mar 20253:14 pmRNSDirector/PDMR Shareholding
27th Mar 202510:08 amRNSHolding(s) in Company
25th Mar 20253:14 pmRNSDirector/PDMR Shareholding
24th Mar 20253:35 pmRNSAnnual Report 2024 and Notice of AGM 2025
24th Mar 20252:24 pmRNSHolding(s) in Company
11th Mar 20257:00 amRNSFull Year Results
6th Mar 20252:06 pmRNSHolding(s) in Company
3rd Mar 20253:35 pmRNSHolding(s) in Company
3rd Feb 202512:26 pmRNSTotal Voting Rights
14th Jan 20257:00 amRNS2024 Trading Statement
2nd Jan 20251:00 pmRNSTotal Voting Rights
10th Dec 20243:47 pmRNSDirectorate Change
2nd Dec 20242:11 pmRNSBlock listing Interim Review
2nd Dec 202412:00 pmRNSTotal Voting Rights
6th Nov 20247:00 amRNSQ3 Trading Statement
5th Nov 20241:31 pmRNSHolding(s) in Company
1st Nov 20243:59 pmRNSTotal Voting Rights
1st Oct 20241:19 pmRNSTotal Voting Rights
24th Sep 202412:25 pmRNSDirector/PDMR Shareholding
2nd Sep 20241:44 pmRNSTotal Voting Rights
8th Aug 20247:00 amRNSHalf Year Results
1st Aug 20242:32 pmRNSTotal Voting Rights
23rd Jul 202410:28 amRNSDirectorate Change
1st Jul 20241:10 pmRNSTotal Voting Rights
19th Jun 20242:48 pmRNSDirector/PDMR Shareholding
3rd Jun 202412:33 pmRNSBlock listing Interim Review
3rd Jun 202411:08 amRNSTotal Voting Rights
23rd May 20247:00 amRNSConfirmation of CFO start date
1st May 20241:11 pmRNSTotal Voting Rights
30th Apr 20242:03 pmRNSDirectorate Change
25th Apr 20242:09 pmRNSResult of AGM
25th Apr 20247:00 amRNSQ1 Trading Statement
2nd Apr 20241:49 pmRNSTotal Voting Rights
28th Mar 202412:53 pmRNSDirector/PDMR Shareholding
25th Mar 20244:47 pmRNSDirector/PDMR Shareholding
25th Mar 20242:07 pmRNSAnnual Report 2023 and Notice of AGM 2024
12th Mar 20241:38 pmRNSDirector/PDMR Shareholding
12th Mar 20247:00 amRNSFull Year Results
11th Jan 20246:00 pmRNSDechra Pharmaceuticals
10th Jan 20247:00 amRNSTrading Statement
1st Dec 20234:48 pmRNSBlock listing Interim Review

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.